Eli Lilly (LLY) “Underperform” Rating Maintained by Analysts at Credit Suisse; The Target Price Given is $84; Investors Bancorp (ISBC) Shorts Lowered By 0.34%

June 21, 2018 - By Maria Brooks

Eli Lilly and Company (NYSE:LLY) Logo

Investors Bancorp Inc (NASDAQ:ISBC) had a decrease of 0.34% in short interest. ISBC’s SI was 8.43M shares in June as released by FINRA. Its down 0.34% from 8.46M shares previously. With 3.23M avg volume, 3 days are for Investors Bancorp Inc (NASDAQ:ISBC)’s short sellers to cover ISBC’s short positions. The SI to Investors Bancorp Inc’s float is 3.48%. The stock decreased 0.15% or $0.02 during the last trading session, reaching $13.39. About 2.85M shares traded or 23.13% up from the average. Investors Bancorp, Inc. (NASDAQ:ISBC) has risen 1.87% since June 21, 2017 and is uptrending. It has underperformed by 10.70% the S&P500. Some Historical ISBC News: ; 26/04/2018 – INVESTORS BANCORP 1Q ADJ EPS 20C, EST. 18C; 26/04/2018 – INVESTORS BANCORP INC ISBC.O – QTRLY NET INTEREST INCOME WAS $172.5, UP 3.2 PCT; 15/05/2018 – Community Investors Bancorp, Inc. Reports Net Income For The Nine Months and Three Months Ended March 31, 2018 and restated Net income for the Six Months ended December 31, 2017; 22/03/2018 – Investors Bancorp Closes Below 200-Day Moving Average; 26/04/2018 – INVESTORS BANCORP 1Q ADJ EPS 20C; 07/03/2018 Community Investors Bancorp, Inc. Declares Quarterly Cash Dividend; 26/04/2018 – INVESTORS BANCORP 1Q NET INTEREST MARGIN 2.85%, EST. 2.84%; 15/05/2018 – Community Investors Bancorp, Inc. Reports Net Income For The Nine Months and Three Months Ended March 31, 2018 and restated Net; 15/05/2018 – Moore Capital Management Buys 1.1% of Investors Bancorp; 21/04/2018 – DJ Investors Bancorp Inc, Inst Holders, 1Q 2018 (ISBC)

Credit Suisse have a $84 target on the stock. The target means a potential downside of -2.64% from Eli Lilly (NYSE:LLY)‘s last close price. This rating was revealed in analysts note on 21 June.

Investors sentiment decreased to 0.9 in Q1 2018. Its down 0.16, from 1.06 in 2017Q4. It worsened, as 27 investors sold Investors Bancorp, Inc. shares while 63 reduced holdings. 27 funds opened positions while 54 raised stakes. 224.58 million shares or 3.56% less from 232.86 million shares in 2017Q4 were reported. Ameritas Inv Partners Inc reported 0.01% of its portfolio in Investors Bancorp, Inc. (NASDAQ:ISBC). Bluecrest Cap Management owns 123,300 shares or 0.05% of their US portfolio. Empyrean Prtnrs L P invested in 3.06% or 4.20M shares. Jefferies Group Inc Lc invested in 19,205 shares. Eidelman Virant holds 0.1% of its portfolio in Investors Bancorp, Inc. (NASDAQ:ISBC) for 11,000 shares. Dimensional Fund Advsr L P owns 8.16 million shares or 0.05% of their US portfolio. Blackrock reported 17.81 million shares. Scotia Capital holds 0.01% or 46,218 shares. 10,972 were accumulated by Cibc Asset Management. Jpmorgan Chase And holds 0.01% in Investors Bancorp, Inc. (NASDAQ:ISBC) or 2.10 million shares. Raymond James & Assoc accumulated 24,286 shares. 10,478 are owned by Sei Invests Co. Prudential Fincl Inc stated it has 91,271 shares. Pl Capital Advsrs Ltd Limited Liability Company accumulated 103,000 shares. Geode Mgmt Limited Co holds 2.60 million shares or 0.01% of its portfolio.

Investors Bancorp, Inc. operates as the holding firm for Investors Bank that provides various banking services and products to individuals and businesses in the United States. The company has market cap of $3.88 billion. It offers deposit products, such as savings, checking, and money market accounts, as well as certificates of deposit. It has a 28.55 P/E ratio. The companyÂ’s loan portfolio includes multi-family, commercial real estate, commercial and industrial, and construction loans; consumer and other loans primarily consisting of home equity loans and home equity lines of credit; and one-to four-family residential mortgage loans secured by one-to four-family residential real estate.

Among 11 analysts covering Investors Bancorp Inc (NASDAQ:ISBC), 4 have Buy rating, 1 Sell and 6 Hold. Therefore 36% are positive. Investors Bancorp Inc had 26 analyst reports since August 4, 2015 according to SRatingsIntel. On Thursday, December 21 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. Compass Point downgraded the shares of ISBC in report on Friday, October 30 to “Neutral” rating. Piper Jaffray maintained Investors Bancorp, Inc. (NASDAQ:ISBC) on Monday, January 29 with “Hold” rating. The stock of Investors Bancorp, Inc. (NASDAQ:ISBC) earned “Buy” rating by Keefe Bruyette & Woods on Thursday, August 31. The rating was maintained by RBC Capital Markets with “Buy” on Friday, October 27. The firm has “Buy” rating by Sandler O’Neill given on Thursday, April 5. On Thursday, June 1 the stock rating was maintained by Keefe Bruyette & Woods with “Buy”. The stock has “Underweight” rating by Barclays Capital on Monday, October 30. As per Tuesday, January 2, the company rating was maintained by Barclays Capital. Barclays Capital maintained the stock with “Underweight” rating in Tuesday, January 30 report.

Among 23 analysts covering Eli Lilly and Company (NYSE:LLY), 14 have Buy rating, 1 Sell and 8 Hold. Therefore 61% are positive. Eli Lilly and Company has $125 highest and $64 lowest target. $93.76’s average target is 8.67% above currents $86.28 stock price. Eli Lilly and Company had 105 analyst reports since July 23, 2015 according to SRatingsIntel. On Monday, July 17 the stock rating was maintained by Jefferies with “Buy”. The stock of Eli Lilly and Company (NYSE:LLY) earned “Overweight” rating by Morgan Stanley on Friday, December 16. On Wednesday, December 13 the stock rating was maintained by Leerink Swann with “Hold”. The company was maintained on Thursday, July 14 by Jefferies. The firm earned “Buy” rating on Monday, July 17 by Deutsche Bank. Jefferies maintained Eli Lilly and Company (NYSE:LLY) on Friday, September 15 with “Buy” rating. Leerink Swann downgraded the shares of LLY in report on Wednesday, July 26 to “Market Perform” rating. Bank of America maintained the stock with “Neutral” rating in Thursday, February 1 report. Leerink Swann maintained the shares of LLY in report on Tuesday, October 13 with “Outperform” rating. The stock has “Outperform” rating by Leerink Swann on Monday, December 28.

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.32, from 1.1 in 2017Q4. It turned negative, as 76 investors sold Eli Lilly and Company shares while 427 reduced holdings. 82 funds opened positions while 308 raised stakes. 810.94 million shares or 1.95% less from 827.08 million shares in 2017Q4 were reported. 182,036 were accumulated by Utah Retirement Sys. Argent Trust Communications holds 0.09% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 3,877 shares. Tci Wealth accumulated 16,481 shares. Advisors Ok reported 3,277 shares. 46,659 are owned by Sterling Cap Mgmt Limited Liability Company. Pub Employees Retirement System Of Ohio holds 0.27% in Eli Lilly and Company (NYSE:LLY) or 659,061 shares. Mirae Asset Global Ltd reported 96,803 shares. 125,930 were reported by Twin Management Inc. Evercore Wealth Management Lc reported 0.07% stake. Legal And General Gru Public Ltd Limited Liability Company has invested 0.28% of its portfolio in Eli Lilly and Company (NYSE:LLY). Cibc World Mkts Corporation has 0.15% invested in Eli Lilly and Company (NYSE:LLY) for 178,718 shares. Rmsincerbeaux Mgmt Ltd Limited Liability Company holds 0.45% or 6,200 shares. Sawgrass Asset Limited Liability owns 0.02% invested in Eli Lilly and Company (NYSE:LLY) for 4,500 shares. Sequoia Fincl Ltd Liability has 3,272 shares. Hallmark Cap Mgmt, New Jersey-based fund reported 22,647 shares.

Since February 1, 2018, it had 1 buying transaction, and 19 insider sales for $92.69 million activity. On Wednesday, April 25 LILLY ENDOWMENT INC sold $14.55 million worth of Eli Lilly and Company (NYSE:LLY) or 180,000 shares. The insider Zakrowski Donald A sold $65,790. Shares for $708,620 were sold by Simmons Jeffrey N on Tuesday, May 1. Shaw Christi had sold 8,426 shares worth $691,775 on Tuesday, May 29. On Thursday, June 14 Skovronsky Daniel bought $862,200 worth of Eli Lilly and Company (NYSE:LLY) or 10,000 shares. Shares for $2.13 million were sold by Conterno Enrique A. 22,544 shares valued at $1.81M were sold by Mahony Susan on Friday, April 13.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on July, 24. They expect $1.34 earnings per share, up 20.72% or $0.23 from last year’s $1.11 per share. LLY’s profit will be $1.37 billion for 16.10 P/E if the $1.34 EPS becomes a reality. After $1.34 actual earnings per share reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Eli Lilly and Company develops, manufactures, and markets pharmaceutical products worldwide. The company has market cap of $88.06 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It has a 80.64 P/E ratio. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

More important recent Eli Lilly and Company (NYSE:LLY) news were published by: Fool.com which released: “Better Buy: Johnson & Johnson vs. Eli Lilly” on June 17, 2018, also Seekingalpha.com published article titled: “Alzheimer’s Disease: A History Of Drug Failures”, Streetinsider.com published: “Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer’s Disease Due to Futility” on June 12, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) was released by: Schaeffersresearch.com and their article: “Analyst: Eli Lilly Assets Are ‘Underappreciated'” with publication date: June 08, 2018.

The stock decreased 0.62% or $0.54 during the last trading session, reaching $86.28. About 4.68M shares traded or 19.45% up from the average. Eli Lilly and Company (NYSE:LLY) has risen 5.65% since June 21, 2017 and is uptrending. It has underperformed by 6.92% the S&P500. Some Historical LLY News: 01/05/2018 – Merck Boosts Outlook as Keytruda Sales Surpass Diabetes Drugs; 10/05/2018 – BioWorld [Reg]: Lilly strikes $1.6B deal to buy I-O player Armo; 10/05/2018 – Eli Lilly: ARMO’s Lead Asset Being Studied in Multiple Tumor Types; 06/04/2018 – Incyte’s new immunotherapy drug epacadostat failed to work in conjunction with Merck’s blockbuster melanoma drug Keytruda; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®; 25/04/2018 – ELI LILLY – PLANS TO COLLABORATE ACROSS 4 INITIATIVES TO ADVANCE SCIENTIFIC UNDERSTANDING OF TYPE 2 DIABETES & RELATED COMPLICATIONS; 16/04/2018 – ASTRAZENECA PLC AZN.L – LYNPARZA TRIAL MET ITS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL; 04/04/2018 – ELI LILLY AND CO – ONLY GRADE; 24/04/2018 – ELI LILLY AND CO – QTRLY REVENUE $5,700.0 MLN VS $5,228.3 MLN REPORTED LAST YEAR; 16/04/2018 – Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: